tirzepatide patent challenge eli lilly BPI labs is challenging the patent. This is a second as Can any patent lawyers give

Keeping a symptom diary that tracks headache timing, intensity, and accompanying symptoms helps your provider determine whether the medication itself is responsible or whether another factor needs addressing

Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from the first of two of its Phase 3 trials that included more than 3,100 overweight or obese adults

The critical role of oxidative stress in the development of asthma has been reported by numerous studies

It is not intended for human or veterinary consumption, medical use, or cosmetic application